Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Cristi Radford, MS, CGC

Authored Items
“Newer” Ovarian Cancer Genes and Option of Risk-Reducing Salpingo-Oophorectomy
Cristi Radford, MS, CGC
Online First published on May 12, 2016 in Genetic Counseling, Online First
T-DM1 in Metastatic Breast Cancer
Cristi Radford, MS, CGC
TOP - August 2012, Vol 5, No 5 published on August 22, 2012 in Breast Cancer
Exploring the Drug Shortage Crisis
Cristi Radford, MS, CGC
TOP - August 2012, Vol 5, No 5 published on August 22, 2012 in Drug Updates
Pharmacists Can Enhance Compliance With Oral Medications
Cristi Radford, MS, CGC
TOP - June 2012, Vol 5, No 4 published on July 2, 2012 in Best Practices
Abstracts of Interest From the 2012 American Society of Clinical Oncology Annual Meeting
Cristi Radford, MS, CGC
TOP - June 2012, Vol 5, No 4 published on July 2, 2012 in Conference Correspondent
Payer Trends in Oncology: Challenges and Solutions
Cristi Radford, MS, CGC
TOP - Special Issue May 2012, Vol 5, No 3 published on May 24, 2012 in Conference Correspondent
What Pharmacists Need to Know About 7 New Agents
Cristi Radford, MS, CGC
TOP - Special Issue May 2012, Vol 5, No 3 published on May 24, 2012 in Drug Updates
Many Febrile Neutropenia Patients Can Be Treated at Home
Cristi Radford, MS, CGC
TOP - April 2012, Vol 5, No 2 published on April 30, 2012 in Supportive Care
What’s New in Antiemetic Control?
Cristi Radford, MS, CGC
TOP - April 2012, Vol 5, No 2 published on April 27, 2012 in Supportive Care
Eribulin Associated With Less Neuropathy Than Ixabepilone in a Prospective, Randomized Study
Cristi Radford, MS, CGC
TOP - February 2012, Vol 5, No 1 published on February 28, 2012 in Breast Cancer
New Bone-Targeting Compound Improves Survival in Metastatic Prostate Cancer
Cristi Radford, MS, CGC
TOP - December 2011, Vol 4, No 8 published on December 23, 2011 in Genitourinary Cancers
Positive Data Continue to Accrue for Crizotinib in ALK-Positive NSCLC
Cristi Radford, MS, CGC
TOP - December 2011, Vol 4, No 8 published on December 23, 2011 in Lung Cancer
Chemoprevention in Breast Cancer: Which Agents for Which Patients?
Cristi Radford, MS, CGC
TOP - October 2011 Vol 4, No 7 published on October 20, 2011 in Conference Correspondent
A Wealth of Targets Identified in Colorectal Cancer
Cristi Radford, MS, CGC
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Colorectal Cancer
Upper GI Cancers: Are We Getting Value for the Money?
Cristi Radford, MS, CGC
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Gastrointestinal Cancers
Optimal Length of Treatment of Non-Hodgkin Lymphoma Debated
Cristi Radford, MS, CGC
TOP - August 2011 Vol 4, No 5 published on August 25, 2011 in Conference Correspondent, Hematologic Cancers
Drug Exposure, Response Rates Associated with Higher Doses of Melphalan
Cristi Radford, MS, CGC
Web Exclusives published on May 26, 2011 in Drug Therapies
Preoperative Treatment with Anti-HER2 Agents Yields Benefits in Key Studies
Cristi Radford, MS, CGC
TOP - February 2011, Vol 4, No 1 published on February 17, 2011
Preoperative Anti-HER2 Agents Yield Benefits
Cristi Radford, MS, CGC
Web Exclusives published on December 23, 2010
Estrogen Alone Poses No Increased Breast Cancer Risk
Cristi Radford, MS, CGC
Web Exclusives published on December 23, 2010
For Breakthrough Cancer Pain, Fentanyl Nasal Spray Easily Titratable and Effective
Cristi Radford, MS, CGC
TOP - December 2010, Vol 3, No 8 published on November 30, 2010
Sex and the Cancer Patient: Still a Problem with Targeted Agents
Cristi Radford, MS, CGC
TOP - December 2010, Vol 3, No 8 published on November 30, 2010
Prolonging Chemotherapy in Metastatic Breast Cancer Improves Survival
Cristi Radford, MS, CGC
TOP - December 2010, Vol 3, No 8 published on November 30, 2010
Novel Agent Has Striking Activity in Lung Cancer Subset
Cristi Radford, MS, CGC
Web Exclusives published on August 10, 2010
Last modified: December 11, 2015